Aims and scope

Expert Opinion on Investigational Drugs [ISSN 1354-3784]; [e-ISSN 1744-7658] is a MEDLINE-indexed, international subscription-based journal publishing rigorously peer-reviewed review articles and original papers on drugs in preclinical and early-stage clinical development, providing expert opinion on the scope for future development. Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development.

Expert Opinion on Investigational Drugs address the needs of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.

The Editors welcome:

• Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies.
• Drug Evaluations reviewing the clinical and pharmacological data on a particular drug.
• Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trials.
  
  

Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections:

Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results;

Article Highlights – an executive summary of the author’s most critical points.

Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees.

Reach an international clinical and medical audience alongside other key option leaders in your field by publishing with Expert Opinion on Investigational Drugs, part of the Expert Collection brand. 

Authors can choose to publish gold open access in this journal.

Read the Instructions for Authors for information on how to submit your article. For any pre-submission enquiries, please contact the Commissioning Editor.